CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Pulmonx Corporation - LUNG CFD

    11.76
    0.17%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.07
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Pulmonx Corp ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 11.74
    Open* 11.49
    1-Year Change* 87.13%
    Day's Range* 11.49 - 11.92
    52 wk Range 5.15-14.28
    Average Volume (10 days) 328.95K
    Average Volume (3 months) 4.73M
    Market Cap 404.53M
    P/E Ratio -100.00K
    Shares Outstanding 38.31M
    Revenue 64.82M
    EPS -1.62
    Dividend (Yield %) N/A
    Beta -100.00K
    Next Earnings Date Feb 20, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 8, 2023 11.76 0.19 1.64% 11.57 11.92 11.38
    Dec 7, 2023 11.74 0.62 5.58% 11.12 11.76 11.12
    Dec 6, 2023 11.44 0.00 0.00% 11.44 11.83 11.32
    Dec 5, 2023 11.58 0.75 6.93% 10.83 11.59 10.82
    Dec 4, 2023 11.25 0.22 1.99% 11.03 11.40 11.03
    Dec 1, 2023 11.21 0.95 9.26% 10.26 11.23 10.26
    Nov 30, 2023 10.86 0.08 0.74% 10.78 11.09 10.76
    Nov 29, 2023 10.99 0.18 1.67% 10.81 11.42 10.81
    Nov 28, 2023 11.01 0.21 1.94% 10.80 11.18 10.79
    Nov 27, 2023 11.06 0.39 3.66% 10.67 11.33 10.67
    Nov 24, 2023 11.00 0.84 8.27% 10.16 11.15 10.16
    Nov 22, 2023 10.58 0.30 2.92% 10.28 10.94 10.28
    Nov 21, 2023 10.54 -0.13 -1.22% 10.67 10.72 10.44
    Nov 20, 2023 10.80 0.44 4.25% 10.36 10.88 10.35
    Nov 17, 2023 10.81 0.05 0.46% 10.76 11.07 10.44
    Nov 16, 2023 10.81 0.28 2.66% 10.53 10.97 10.36
    Nov 15, 2023 10.79 0.25 2.37% 10.54 11.38 10.54
    Nov 14, 2023 10.95 0.58 5.59% 10.37 11.06 10.34
    Nov 13, 2023 10.00 0.92 10.13% 9.08 10.03 9.08
    Nov 10, 2023 9.22 0.07 0.77% 9.15 9.31 8.93

    Pulmonx Corporation Events

    Time (UTC) Country Event
    Tuesday, February 20, 2024

    Time (UTC)

    21:00

    Country

    US

    Event

    Q4 2023 Pulmonx Corp Earnings Release
    Q4 2023 Pulmonx Corp Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 53.662 48.416 32.733 32.595 20.004
    Revenue 53.662 48.416 32.733 32.595 20.004
    Cost of Revenue, Total 13.797 12.786 11.531 10.181 7.718
    Gross Profit 39.865 35.63 21.202 22.414 12.286
    Total Operating Expense 112.299 95.72 65.065 50.433 35.056
    Selling/General/Admin. Expenses, Total 83.105 69.871 46.074 34.203 20.347
    Research & Development 15.397 13.063 7.46 6.049 6.991
    Operating Income -58.637 -47.304 -32.332 -17.838 -15.052
    Interest Income (Expense), Net Non-Operating 0.063 -1.029 -2.868 -1.785 -2.199
    Other, Net 0.004 0.015 3.182 -0.717 -1.216
    Net Income Before Taxes -58.57 -48.318 -32.018 -20.34 -18.467
    Net Income After Taxes -58.923 -48.661 -32.231 -20.703 -18.479
    Net Income Before Extra. Items -58.923 -48.661 -32.231 -20.703 -18.479
    Net Income -58.923 -48.661 -32.231 -20.703 -18.479
    Income Available to Common Excl. Extra. Items -58.923 -48.661 -32.231 -20.703 -18.479
    Income Available to Common Incl. Extra. Items -58.923 -48.661 -32.231 -20.703 -18.479
    Diluted Net Income -58.923 -48.661 -32.231 -20.703 -18.479
    Diluted Weighted Average Shares 37.0965 36.1294 35.6937 33.9254 33.9254
    Diluted EPS Excluding Extraordinary Items -1.58837 -1.34685 -0.90299 -0.61025 -0.54469
    Dividends per Share - Common Stock Primary Issue 0 0
    Diluted Normalized EPS -1.58837 -1.34685 -0.90299 -0.61025 -0.54469
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 17.194 14.535 15.425 13.502 13.95
    Revenue 17.194 14.535 15.425 13.502 13.95
    Cost of Revenue, Total 4.46 3.946 4.241 3.35 3.532
    Gross Profit 12.734 10.589 11.184 10.152 10.418
    Total Operating Expense 33.633 30.935 30.052 27.433 28.361
    Selling/General/Admin. Expenses, Total 23.463 22.736 21.908 19.717 21.235
    Research & Development 5.71 4.253 3.903 4.366 3.594
    Operating Income -16.439 -16.4 -14.627 -13.931 -14.411
    Interest Income (Expense), Net Non-Operating 0.346 0.656 0.589 -0.209 -0.224
    Other, Net 0.038 0.008 0.001 -0.032 0.035
    Net Income Before Taxes -16.055 -15.736 -14.037 -14.172 -14.6
    Net Income After Taxes -16.195 -15.86 -14.283 -14.172 -14.64
    Net Income Before Extra. Items -16.195 -15.86 -14.283 -14.172 -14.64
    Net Income -16.195 -15.86 -14.283 -14.172 -14.64
    Income Available to Common Excl. Extra. Items -16.195 -15.86 -14.283 -14.172 -14.64
    Income Available to Common Incl. Extra. Items -16.195 -15.86 -14.283 -14.172 -14.64
    Diluted Net Income -16.195 -15.86 -14.283 -14.172 -14.64
    Diluted Weighted Average Shares 37.8183 37.5724 37.3828 37.1903 37.0034
    Diluted EPS Excluding Extraordinary Items -0.42823 -0.42212 -0.38207 -0.38107 -0.39564
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.42823 -0.42212 -0.38207 -0.38107 -0.39564
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 168.953 208.002 249.989 41.071 11.308
    Cash and Short Term Investments 141.138 180.041 231.561 28.347 4.124
    Cash 97.089 141.239 221.028 7.449 4.073
    Cash & Equivalents 4.647 0.831 10.533 6.318 0.051
    Short Term Investments 39.402 37.971 0 14.58 0
    Total Receivables, Net 9.279 6.924 4.567 5.898 3.421
    Accounts Receivable - Trade, Net 8.677 6.562 4.228 5.511 2.95
    Total Inventory 14.564 16.285 10.741 5.612 3.32
    Prepaid Expenses 3.451 4.174 2.512 0.448 0.318
    Other Current Assets, Total 0.521 0.578 0.608 0.766 0.125
    Total Assets 193.676 235.173 263.708 53.533 15.013
    Property/Plant/Equipment, Total - Net 10.5 12.889 10.45 7.463 0.375
    Property/Plant/Equipment, Total - Gross 14.056 15.132 12.223 8.903 2.12
    Accumulated Depreciation, Total -3.556 -2.243 -1.773 -1.44 -1.745
    Goodwill, Net 2.333 2.333 2.333 2.333 2.333
    Intangibles, Net 0.154 0.277 0.4 0.524 0.647
    Other Long Term Assets, Total 5.812 0.731 0.536 2.142 0.35
    Total Current Liabilities 18.492 17.55 12.526 14.161 8.072
    Accounts Payable 1.758 1.582 1.472 2.681 1.289
    Accrued Expenses 15.988 14.345 9.624 9.125 5.496
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.656 1.532 1.43 2.355 1.287
    Total Liabilities 39.669 41.934 37.574 35.572 41.804
    Total Long Term Debt 17.234 17.324 17.368 14.965 33.605
    Long Term Debt 17.234 17.324 17.368 14.965 33.605
    Deferred Income Tax 0.094 0.037 0.062 0.043 0.048
    Other Liabilities, Total 3.849 7.023 7.618 6.403 0.079
    Total Equity 154.007 193.239 226.134 17.961 -26.791
    Preferred Stock - Non Redeemable, Net 0 0 0 205.339 140.535
    Common Stock 0.038 0.037 0.036 0.019 0.017
    Additional Paid-In Capital 502.712 482.885 467.147 21.733 21.124
    Retained Earnings (Accumulated Deficit) -350.318 -291.395 -242.734 -210.503 -189.8
    Other Equity, Total 1.575 1.712 1.685 1.373 1.333
    Total Liabilities & Shareholders’ Equity 193.676 235.173 263.708 53.533 15.013
    Total Common Shares Outstanding 37.5556 36.9318 35.6937 33.9254 33.9254
    Long Term Investments 5.924 10.941
    Current Port. of LT Debt/Capital Leases 0.09 0.091
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 147.364 164.428 181.298 168.953 183.111
    Cash and Short Term Investments 116.482 135.152 152.836 141.138 156.899
    Cash 67.777 76.596 84.95 97.089 107.308
    Cash & Equivalents 27.168 24.985 25.457 4.647 2.849
    Short Term Investments 21.537 33.571 42.429 39.402 46.742
    Total Receivables, Net 10.92 9.83 8.845 9.279 7.619
    Accounts Receivable - Trade, Net 10.091 8.941 8.171 8.677 7.221
    Total Inventory 16.131 15.636 15.588 14.564 15.568
    Prepaid Expenses 3.402 3.226 3.651 3.451 2.611
    Other Current Assets, Total 0.429 0.584 0.378 0.521 0.414
    Total Assets 185.016 193.113 201.272 193.676 202.203
    Property/Plant/Equipment, Total - Net 8.126 8.924 9.642 10.5 11.328
    Property/Plant/Equipment, Total - Gross 12.765 13.208 13.559 14.056 14.529
    Accumulated Depreciation, Total -4.639 -4.284 -3.917 -3.556 -3.201
    Goodwill, Net 2.333 2.333 2.333 2.333 2.333
    Intangibles, Net 0.062 0.092 0.123 0.154 0.185
    Long Term Investments 23.271 12.454 2.637 5.924 0
    Other Long Term Assets, Total 3.86 4.882 5.239 5.812 5.246
    Total Current Liabilities 20.485 19.521 17.079 18.492 21.686
    Accounts Payable 3.189 2.377 2.89 1.758 2.648
    Accrued Expenses 16.765 16.571 13.595 15.988 13.211
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0.091 0.093 0.091 0.09 5.043
    Other Current Liabilities, Total 0.44 0.48 0.503 0.656 0.784
    Total Liabilities 59.273 59.161 57.338 39.669 38.721
    Total Long Term Debt 37.154 37.147 37.173 17.234 12.34
    Long Term Debt 37.154 37.147 37.173 17.234 12.34
    Deferred Income Tax 0.097 0.094 0.071 0.094 0.051
    Other Liabilities, Total 1.537 2.399 3.015 3.849 4.644
    Total Equity 125.743 133.952 143.934 154.007 163.482
    Preferred Stock - Non Redeemable, Net 0 0 0 0 0
    Common Stock 0.038 0.038 0.038 0.038 0.037
    Additional Paid-In Capital 521.034 514.331 508.254 502.712 498.083
    Retained Earnings (Accumulated Deficit) -397.273 -382.373 -366.178 -350.318 -336.035
    Other Equity, Total 1.944 1.956 1.82 1.575 1.397
    Total Liabilities & Shareholders’ Equity 185.016 193.113 201.272 193.676 202.203
    Total Common Shares Outstanding 38.3014 38.0167 37.7307 37.5556 37.408
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -58.923 -48.661 -32.231 -20.703 -18.479
    Cash From Operating Activities -45.083 -41.388 -30.633 -20.765 -18.394
    Cash From Operating Activities 1.513 0.867 0.483 0.365 0.27
    Non-Cash Items 19.341 14.252 5.902 1.974 1.338
    Cash Taxes Paid 0.398 0.322 0.259 0.196 0.226
    Cash Interest Paid 0.847 0.722 3.059 1.396 1.361
    Changes in Working Capital -7.014 -7.846 -4.787 -2.401 -1.523
    Cash From Investing Activities -4.225 -46.255 12.694 -14.233 0.2
    Capital Expenditures -1.318 -3.671 -0.911 -0.72 -0.316
    Other Investing Cash Flow Items, Total -2.907 -42.584 13.605 -13.513 0.516
    Cash From Financing Activities 2.419 4.456 234.831 45.619 12.114
    Financing Cash Flow Items -0.053 -0.041 -4.499 -0.568 0
    Issuance (Retirement) of Stock, Net 2.559 4.497 206.337 40.187 0.114
    Issuance (Retirement) of Debt, Net -0.087 0 32.993 6 12
    Foreign Exchange Effects 0.145 0.106 0.133 0.022 0.154
    Net Change in Cash -46.744 -83.081 217.025 10.643 -5.926
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -15.86 -58.923 -44.64 -30.468 -15.828
    Cash From Operating Activities -12.644 -45.083 -35.277 -24.59 -15.026
    Cash From Operating Activities 0.437 1.513 1.127 0.744 0.368
    Non-Cash Items 5.373 19.341 14.434 9.286 4.212
    Cash Taxes Paid 0.092 0.398 0.337 0.228 0.029
    Cash Interest Paid 0.00036 0.847 0.628 0.375 0.178
    Changes in Working Capital -2.594 -7.014 -6.198 -4.152 -3.778
    Cash From Investing Activities 0.574 -4.225 -3.498 -3.542 -5.622
    Capital Expenditures -0.061 -1.318 -1.142 -0.863 -0.564
    Other Investing Cash Flow Items, Total 0.635 -2.907 -2.356 -2.679 -5.058
    Cash From Financing Activities 20.72 2.419 2.352 1.446 1.315
    Financing Cash Flow Items -0.053 0 0 0
    Issuance (Retirement) of Stock, Net 0.72 2.559 2.396 1.49 1.315
    Issuance (Retirement) of Debt, Net 20 -0.087 -0.044 -0.044
    Foreign Exchange Effects 0.021 0.145 0.345 0.153 0.021
    Net Change in Cash 8.671 -46.744 -36.078 -26.533 -19.312
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    PRIMECAP Management Company Investment Advisor 14.515 5519721 17000 2023-06-30
    Point72 Asset Management, L.P. Hedge Fund 8.7464 3326065 242815 2023-06-30 HIGH
    BlackRock Institutional Trust Company, N.A. Investment Advisor 6.0208 2289587 198017 2023-06-30 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 5.2557 1998614 -590541 2023-06-30 LOW
    Fidelity Management & Research Company LLC Investment Advisor 4.2811 1628005 665507 2023-06-30 LOW
    Morgan Stanley & Co. LLC Research Firm 3.5521 1350793 -370855 2023-06-30 MED
    Deerfield Management Company, L.P. Hedge Fund 2.7987 1064285 -1338419 2023-06-30 MED
    Braidwell LP Hedge Fund 2.628 999362 -163932 2023-06-30 HIGH
    Kleiner, Perkins, Caufield & Byers Venture Capital 2.6164 994971 0 2023-06-30 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 2.5971 987616 40639 2023-06-30 LOW
    Victory Capital Management Inc. Investment Advisor/Hedge Fund 2.5701 977344 977344 2023-06-30 LOW
    French (Glendon E III) Individual Investor 2.4103 916595 -6527 2023-09-01 LOW
    BNP Paribas Asset Management USA, Inc. Investment Advisor 2.3872 907792 -69239 2023-06-30 LOW
    BNP Paribas Asset Management UK Limited Investment Advisor 2.3602 897525 0 2023-09-30 MED
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.938 736993 36851 2023-06-30 LOW
    Franklin Advisers, Inc. Investment Advisor/Hedge Fund 1.9137 727752 17494 2023-06-30 LOW
    Jacobs Levy Equity Management, Inc. Investment Advisor/Hedge Fund 1.9083 725667 46928 2023-06-30 MED
    D. E. Shaw & Co., L.P. Hedge Fund 1.8838 716378 142214 2023-06-30 MED
    Rock Springs Capital Management LP Hedge Fund 1.7156 652400 0 2023-06-30 LOW
    Pura Vida Investments, LLC Hedge Fund 1.6735 636408 -1105 2023-06-30 HIGH

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Pulmonx Corporation Company profile

    About Pulmonx Corp

    Pulmonx Corporation is a commercial-stage medical technology company. The Company provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The Company’s solutions include Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System and StratX Lung Analysis Platform, which is designed to treat severe emphysema patients. Its solution provides bronchoscopic lung volume reduction without surgery. The Zephyr Valves are indicated for bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valves are placed in the airways to occlude the diseased parts of the lung, allowing trapped air to escape.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Pulmonx Corp revenues increased 48% to $48.4M. Net loss increased 51% to $48.7M. Revenues reflect United States segment increase of 54% to $25M, Europe, Middle-East and Africa ("EMEA") segment increase of 44% to $19.9M. Higher net loss reflects Selling, general and administrative increase of 41% to $61.2M (expense), Stock-based Compensation in SGA increase from $2.8M to $8.7M (expense).

    Industry: Medical Equipment

    700 Chesapeake Dr
    REDWOOD CITY
    CALIFORNIA 94063
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    Gold

    2,004.85 Price
    -1.180% 1D Chg, %
    Long position overnight fee -0.0198%
    Short position overnight fee 0.0116%
    Overnight fee time 22:00 (UTC)
    Spread 0.50

    XRP/USD

    0.70 Price
    +2.450% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    US100

    16,080.90 Price
    +0.500% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 7.0

    Oil - Crude

    71.41 Price
    +2.320% 1D Chg, %
    Long position overnight fee -0.0204%
    Short position overnight fee -0.0015%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading